Seamus Mulligan, Director at Jazz Pharmaceuticals plc (JAZZ), sold 46,436 shares at $126.65 ($6.0M) on 2016-08-25, disclosed to the SEC on 2016-08-26.
Seasonal sale ($6.0M) by Director — this insider has traded JAZZ in August in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $126.65 | 3,565 | $452K | 7.6% |
| 2 | $126.65 | 3,565 | $452K | 7.6% |
| 3 | $127.70 | 9,500 | $1.2M | 20.3% |
| 4 | $128.97 | 10,283 | $1.3M | 22.2% |
| 5 | $128.97 | 10,283 | $1.3M | 22.2% |
| 6 | $129.42 | 4,620 |
| $598K |
| 10.0% |
| 7 | $129.42 | 4,620 | $598K | 10.0% |
| Total | $128.44 avg | 46,436 | $6.0M | 100% |
| Filing → |
| JAZZ | BUY | 2018-11-19 | $14.2M | — | Filing → |
| JAZZ | SELL | 2016-05-26 | $8.2M | — | Filing → |
| JAZZ | SELL | 2016-02-24 | $6.9M | — | Filing → |